Compare ECO & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ECO | CDNA |
|---|---|---|
| Founded | 2018 | 1998 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.6B |
| IPO Year | 2023 | 2007 |
| Metric | ECO | CDNA |
|---|---|---|
| Price | $85.52 | $66.83 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $61.34 | $58.83 |
| AVG Volume (30 Days) | 679.1K | ★ 1.0M |
| Earning Date | 11-11-2026 | 11-03-2026 |
| Dividend Yield | ★ 11.81% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.13 |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | $107.77 | $30.36 |
| Revenue Next Year | N/A | $6.23 |
| P/E Ratio | ★ $18.60 | $30.04 |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $27.74 | $13.95 |
| 52 Week High | $87.31 | $65.50 |
| Indicator | ECO | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 64.37 | 78.88 |
| Support Level | $47.47 | $17.26 |
| Resistance Level | $87.31 | N/A |
| Average True Range (ATR) | 3.21 | 2.87 |
| MACD | -0.55 | 0.90 |
| Stochastic Oscillator | 52.82 | 99.39 |
Okeanis Eco Tankers Corp is an international owner and operator of a fleet of tanker vessels used for the transportation of crude oil. Its fleet consists of modern Suezmax and VLCC tankers that are designed in accordance with eco-efficiency standards, including features such as reduced fuel consumption, exhaust gas cleaning systems, and ballast water treatment systems. All of the company's revenue is derived from a single segment, the crude oil tanker segment. Geographically, the maximum revenue is generated from Europe, and the rest from Asia, North America, and South America.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.